EA202090800A1 - Новые анти-cd3-эпсилон антитела - Google Patents

Новые анти-cd3-эпсилон антитела

Info

Publication number
EA202090800A1
EA202090800A1 EA202090800A EA202090800A EA202090800A1 EA 202090800 A1 EA202090800 A1 EA 202090800A1 EA 202090800 A EA202090800 A EA 202090800A EA 202090800 A EA202090800 A EA 202090800A EA 202090800 A1 EA202090800 A1 EA 202090800A1
Authority
EA
Eurasian Patent Office
Prior art keywords
new anti
epsilon antibodies
seq
group
cdr sequences
Prior art date
Application number
EA202090800A
Other languages
English (en)
Inventor
Цзин Ли
Цинь Мей
Original Assignee
Уси Байолоджикс Аэлэнд Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Уси Байолоджикс Аэлэнд Лимитед filed Critical Уси Байолоджикс Аэлэнд Лимитед
Publication of EA202090800A1 publication Critical patent/EA202090800A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Abstract

Представлены выделенные моноклональные анти-CD3-эпсилон антитела или их антигенсвязывающие фрагменты, включающие одну или несколько последовательностей CDR тяжелой цепи, выбранных из группы, состоящей из SEQ ID NO: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45 и 47, и/или одну или несколько последовательностей CDR каппа-легкой цепи, выбранных из группы, состоящей из SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 и 48. Также представлены кодирующие их выделенные полинуклеотиды, включающие их фармацевтические композиции и их применение.
EA202090800A 2017-09-21 2018-09-20 Новые анти-cd3-эпсилон антитела EA202090800A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017102622 2017-09-21
PCT/CN2018/106618 WO2019057099A1 (en) 2017-09-21 2018-09-20 NOVEL ANTI-CD3EPSILON ANTIBODIES

Publications (1)

Publication Number Publication Date
EA202090800A1 true EA202090800A1 (ru) 2020-08-11

Family

ID=65811028

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090800A EA202090800A1 (ru) 2017-09-21 2018-09-20 Новые анти-cd3-эпсилон антитела

Country Status (15)

Country Link
US (2) US11440962B2 (ru)
EP (1) EP3684806A4 (ru)
JP (2) JP7305624B2 (ru)
KR (1) KR20200055052A (ru)
CN (2) CN115991777A (ru)
AU (1) AU2018336519A1 (ru)
BR (1) BR112020004992A2 (ru)
CA (1) CA3074130A1 (ru)
EA (1) EA202090800A1 (ru)
IL (1) IL273393A (ru)
MX (1) MX2020003087A (ru)
SG (1) SG11202001358RA (ru)
TW (1) TWI820041B (ru)
WO (1) WO2019057099A1 (ru)
ZA (1) ZA202001314B (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020005676A2 (pt) 2017-09-22 2020-10-20 WuXi Biologics Ireland Limited novos complexos polipeptídicos biespecíficos
MX2020003144A (es) 2017-09-22 2020-07-28 Wuxi Biologics Ireland Ltd Nuevos complejos de polipeptidos biespecificos cd3/cd19.
CN114174339A (zh) * 2019-06-07 2022-03-11 阿迪马布有限责任公司 高亲和力抗cd3抗体及其产生和使用方法
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
PE20230389A1 (es) * 2020-05-27 2023-03-06 Janssen Biotech Inc Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
US20230279138A1 (en) * 2020-07-27 2023-09-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Novel bispecific anti-cd3/cd20 polypeptide complex formulation
US11795224B2 (en) * 2021-03-24 2023-10-24 China Medical University Hospital Anti-T-cell nanobody and nucleic acid encoding sequence thereof, and uses of the same
CN115536740A (zh) * 2021-06-30 2022-12-30 苏州方德门达新药开发有限公司 介导细胞内有效滞留cd3的空间构象表位及其应用
CN115558023A (zh) * 2021-07-02 2023-01-03 安源医药科技（上海）有限公司 抗cd3抗体及其用途
WO2023173258A1 (zh) * 2022-03-14 2023-09-21 成都盛世君联生物技术有限公司 一种抗cd3抗体及其制备方法和用途
CN115286715B (zh) * 2022-05-18 2023-05-23 上海百英生物科技股份有限公司 一种抗cd3的纳米抗体或其抗原结合部分及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
CA2625440C (en) 2005-10-11 2023-06-13 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
CA2682626A1 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
JP2010524851A (ja) * 2007-04-03 2010-07-22 マイクロメット アーゲー 種間特異的結合ドメイン
WO2011109588A1 (en) 2010-03-03 2011-09-09 Health Research Inc. Novel cd3 epsilon immunogens and antibodies
SG11201509361TA (en) 2013-05-28 2015-12-30 Numab Ag Novel antibodies
PL3192812T3 (pl) 2013-12-17 2020-10-19 Genentech, Inc. Przeciwciała anty-CD3 i sposoby ich zastosowania
CN106459201A (zh) 2014-05-28 2017-02-22 豪夫迈·罗氏有限公司 结合人和食蟹猴CD3ε的抗体
EP3204415B1 (en) * 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
EP4039710A3 (en) 2015-01-23 2022-10-19 Sanofi Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123

Also Published As

Publication number Publication date
AU2018336519A1 (en) 2020-03-05
US11440962B2 (en) 2022-09-13
IL273393A (en) 2020-05-31
US20230192850A1 (en) 2023-06-22
EP3684806A4 (en) 2021-09-22
CN111108119B (zh) 2022-11-15
NZ762170A (en) 2023-10-27
KR20200055052A (ko) 2020-05-20
WO2019057099A1 (en) 2019-03-28
BR112020004992A2 (pt) 2020-10-06
CN115991777A (zh) 2023-04-21
US20200299384A1 (en) 2020-09-24
ZA202001314B (en) 2021-08-25
CA3074130A1 (en) 2019-03-28
EP3684806A1 (en) 2020-07-29
SG11202001358RA (en) 2020-03-30
TWI820041B (zh) 2023-11-01
TW201922787A (zh) 2019-06-16
MX2020003087A (es) 2020-08-17
JP2023126851A (ja) 2023-09-12
CN111108119A (zh) 2020-05-05
JP2020534830A (ja) 2020-12-03
JP7305624B2 (ja) 2023-07-10

Similar Documents

Publication Publication Date Title
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
EA201991577A1 (ru) Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер
NZ630610A (en) Tau peptides, anti-tau antibodies, and methods of use thereof
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
EA034770B8 (ru) Человеческие антитела к pd-1
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
PE20190737A1 (es) Anticuerpos anti-cd27
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
RS54452B1 (en) INGREDIENTS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
WO2020014473A8 (en) TGFβ1 INHIBITORS AND USE THEREOF
CY1123275T1 (el) Μορια συνδεσης ειδικα για il-21 και χρησεις αυτων
AR096601A1 (es) Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
CL2018003608A1 (es) Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703)
NZ728981A (en) Anti-ceramide antibodies
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
PH12021550244A1 (en) Anti-btla antibody
MX2020003093A (es) Anticuerpos anti-cd19 novedosos.
PH12017500699A1 (en) Antibodies that bind to ccr6 and their uses
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.